BioNTech pays $25M upfront to strengthen ADC bond with China's MediLink

After penning a couple of antibody-drug conjugate (ADC) deals in 2023, BioNTech has returned to MediLink Therapeutics to further pad out its portfolio.

This time, BioNTech is handing over $25 million upfront for the chance to apply MediLink’s solid-tumor-focused TMALIN ADC platform to several undisclosed targets selected by the German biotech. Suzhou, China-based MediLink will also be in line for up to $1.8 billion in milestones.